← Eichor
Study identifier: NCT04280510 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pathogenic Study of Adult Immune Enteropathies

Condition: Celiac Disease · Autoimmune Enteropathy · Inflammatory Bowel Diseases  ·  Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

PhaseN/A
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Georgia MALAMUT, MD, PhD  ·  33 1 58 41 41 76  ·  georgia.malamut@aphp.fr

Anaïs LEVESCOT, MD, PhD  ·  33 1 42 75 42 77  ·  anais.levescot@inserm.fr

Always discuss trial participation with your own doctor first.

Locations (4)

Hôpital Henri MondorCréteil, FranceNot Yet Recruiting
Hôpital BicêtreLe Kremlin-Bicêtre, FranceNot Yet Recruiting
Hôpital Saint LouisParis, FranceNot Yet Recruiting
Hôpital CochinParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04280510